Ladenburg Thalmann Boosts Price Target on BioDelivery Sciences (BDSI) to $9
More News related to BDSI
- BioDelivery Sciences to Present at the Lazard Capital Markets 6th Annual Healthcare Conference
- Meda Launches Onsolis(TM) (Fentanyl Buccal Soluble Film) for the Treatment of Breakthrough Cancer Pain in Opioid Tolerant Patients
- BioDelivery Sciences International, Inc. (BDSI) President and Chief Executive Officer to Ring The NASDAQ Stock Market Opening Bell
- BioDelivery Sciences and Meda Launch ONSOLIS (fentanyl buccal soluble film)
- BioDelivery Sciences (BDS) Announces $1.3M U.S. Army Grant
More News related to Analyst Comments
- After-Hours Movers 12/02: KTCC, PSS, SEAC, BAC Higher; SIGM, SNPS, ARO, JAS, VRTX Lower
- Trading Radar for 12/3: Marvell (MRVL), Toll Bros. (TOL), Del Monte (DLM), Smith & Wesson (SWHC) Report
- Unusual 11 Mid-Day Movers 12/02: ABCW, BIOF, GRH, STEM Higher; HEB, HDY, BGP, CBAK Lower
- Notable ETF Movers 12/2: GDX, TUR Up; UNG, USO, THD Down
- Notable Analyst Rating Changes 12/2: AMR/UAUA, RFMD, STI, SAY, KBH, BBT Upgraded; STZ, MTL, BWP, POM Downgraded
Ladenburg Thalmann raises its price target on BioDelivery Sciences International Inc. (Nasdaq: BDSI) from $6.5 to $9, reiterating their Buy rating.
BioDelivery Sciences International, Inc. operates as a specialty pharmaceutical company in the United States.
Real-Time Market Moving News Two-Weeks FREE http://www.streetinsider.com/premium_content.php
Related Categories
Analyst CommentsStocks Mentioned
+0.09Related Entities
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
